Funding for this research was provided by:
Austrian Science Fund (P30461)
Text and Data Mining valid from 2020-03-20
Received: 27 January 2020
Accepted: 2 March 2020
First Online: 20 March 2020
Ethics approval and consent to participate
: All experiments concerning mice were carried out respecting the ARRIVE guidelines and the U.K. Animals (Scientific Procedures Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments) and were approved by the national ethical committee on animal care and use (BMBWF-66.009/0175-V/3b/2019- Bundesministerium für Wissenschaft und Forschung).
: Not applicable.
: MY and RJD are past recipients of research grants from Alnylam Pharmaceuticals and Recordati Rare Diseases. They are co-inventors of a patent licensed to Alnylam Pharmaceuticals for RNAi therapy of the acute hepatic porphyrias. RJD is a consultant for Alnylam Pharmaceuticals, Recordati Rare Diseases, and Mitsubishi Tanabe Pharma Development America. The other authors declare no conflict of interest.